COMMUNIQUÉS West-GlobeNewswire

Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
05/02/2026
The study, which assessed the pharmacokinetics, safety, tolerability and immunogenicity of AVT80 compared to Entyvio ® in healthy adult participants, met all its primary endpoints REYKJAVIK, Iceland, Feb. 05, 2026 ( [...]
Biocomposites gains MDR certification for STIMULAN® Rapid Cure and STIMULAN® Kit
05/02/2026
STIMULAN ® certified to be mixed with a combination of Gram-positive and Gram-negative antibiotics STIMULAN ® certified to resolve infection and reduce the need for secondary surgery STIMULAN ® is the only calcium [...]
Zelluna ASA: Invitation to Fourth Quarter 2025 Results Webcast Presentation
05/02/2026
Oslo, Norway, 5 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, invites to a webcast presentation [...]
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
05/02/2026
The study, which assessed the pharmacokinetics, safety, tolerability and immunogenicity of AVT80 compared to Entyvio® in healthy adult participants, met all its primary endpoints REYKJAVIK, ICELAND (February 5, 2026) – [...]
Fagron obtains regulatory clearance for the acquisition of Vepakum in Brazil and completes the acquisition of Magilab in Hungary
05/02/2026
Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 5 February 2026 Fagron obtains regulatory clearance for the acquisition of Vepakum in Brazil and completes the acquisition of [...]
Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer
05/02/2026
BMC128 was developed by Biomica, Evogene’s subsidiary, and is currently completing Phase 1 clinical study, showing promising early clinical results REHOVOT, Israel and SHANGHAI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Evogene [...]
GN Annual Report 2025: Solid execution leading to market share gains, DKK 1.1 billion free cash flow, and a strong foundation for profitable growth in the years ahead
05/02/2026
2025 highlights GN delivered revenue of DKK 16.8 billion with organic revenue growth of -1% (excluding wind-down), The Hearing division took market share – for the 4 th consecutive year – leading to 5% organic revenue [...]
TruFull CBD Gummies: Product Disclosure Information Updated as CBD Supplement Research Grows in 2026
05/02/2026
Examining hemp-derived CBD supplement disclosures, third-party testing verification, THC-free claims, ingredient transparency, refund policies, and what consumers evaluate when researching full-spectrum CBD gummies in [...]
Neura Cognitive Health Supplement: Ingredient Facts, Label Guide, and Consumer Information for 2026
05/02/2026
An informational overview examining ingredient-level research context, Supplement Facts interpretation, and evaluation factors consumers consider when researching cognitive health supplement options New York, NY, Feb. [...]
Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering
05/02/2026
MILLBRAE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing important, innovative medicines to address serious unmet [...]
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
04/02/2026
Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other [...]
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
04/02/2026
CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living [...]
Monthly information on share capital and company voting rights
04/02/2026
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
STERIS Announces Financial Results for Fiscal 2026 Third Quarter
04/02/2026
Total revenue from continuing operations increased 9%; constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.96; adjusted EPS increased to $2.53 Fiscal 2026 outlook [...]
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/02/2026
BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that [...]
PROCEPT BioRobotics® to Attend the TD Cowen 46th Annual Health Care Conference and the 2026 Leerink Global Healthcare Conference
04/02/2026
SAN JOSE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, [...]
Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026
04/02/2026
COPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report full year 2025 financial results and provide a business update on Wednesday, February 11, 2026 [...]
IRADIMED CORPORATION to Hold Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 10, 2026
04/02/2026
ORLANDO, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 fourth quarter and full year financial results before the market opens on [...]
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04/02/2026
NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on February 1, 2026, the [...]

Pages